Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | Director · President, R&D | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TAKEDA PHARMACEUTICAL CO LTD
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | IndirectBy Trust | 145,465 |
Reported balance
After 2026-09-02 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 116,191 · Balance 145,465 F1: The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026. |
| American Depositary SharesSEC Table I · non-derivative | Direct | 766,569 |
Reported balance
Holding disclosure · report date 2026-09-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 766,569 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 4, 2026 01:49 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | SaleAmerican Depositary Shares | 116,191 | $18.49 | $2,148,371.59 |
DisclosureSEC source: 0001395064-26-000335 · wk-form4_1788486556.xml · nonDerivative · entry 1 Plump Andrew Stewart · CIK 0001977689 · Director · President, R&D 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 145,465 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 20:30 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | SaleAmerican Depositary Shares | 19,651 | $18.49 | $363,346.99 |
DisclosureSEC source: 0001493152-26-039693 · ownership.xml · nonDerivative · entry 1 Plump Andrew Stewart · CIK 0001977689 · Director · President, R&D 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 261,656 F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 01:50 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | SaleAmerican Depositary Shares | 165,393 | $17.10 | $2,828,220.30 |
DisclosureSEC source: 0001493152-26-037507 · ownership.xml · nonDerivative · entry 1 Plump Andrew Stewart · CIK 0001977689 · Director · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766,569 F1 · kind: Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:01 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantAmerican Depositary Shares | 125,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000244 · wk-form4_1783375271.xml · nonDerivative · entry 1 Plump Andrew Stewart · CIK 0001977689 · Director · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 931,962 F1 · kind: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 10:07 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantAmerican Depositary Shares | 212,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000136 · wk-form4_1777370848.xml · nonDerivative · entry 1 Plump Andrew Stewart · CIK 0001977689 · Director · President, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 806,572 F1 · kind: On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones. On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above. F2 · balance_after: Includes 464.432 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (329,478 shares), July 1, 2027 (91,580 shares) and July 1, 2028 (43,374 shares). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.